Next week's Proactive forum promises to be a dynamic evening as it showcases some of the most exciting non-resource companies, which are hot on the market right now.
Please ensure you don't miss out by booking your place HERE...
Funding is always a sticking point for junior companies, but cancer diagnostics specialist ValiRx (LON:VAL) has tied up the backing it needs to carry it to “serious inflection points in the clinical programmes”.
Most of this money will be going towards the development of its lead product VAL201 for prostate cancer – the market for which is expected to reach $5bn by next year.
Human trials have just begun and the results could be a catalyst for the share price in 2014.
Satu Vainikka, CEO, will be joining us to explain how important these are to the company, as well as more about the rest of its portfolio.
e-Therapeutics plc (AIM:ETX) has two highly promising early stage drugs going through trials at present.
ETS2101, addressing solid tumours and brain cancer, has just seen very promising results from its UK phase one trial in a variety of solid tumours.
E-Therapeutics' treatment for depression, meanwhile, is progressing through phase II trials.
For a biotech, it is extremely well-funded with cash of more than £45mln on its balance at the time of the last results and it is rapidly garnering fans.
One broker last year said that e-Therapeutics’ technology platform may revolutionise the way the pharmaceutical industry conducts drug development.
Joining us to explain the science and the potential will be chief executive Malcolm Young.
Oxford Pharmascience (AIM:OXP) is at a critical point in its evolution.
A strengthening of the balance sheet last year means it is now primed to take its pipeline of non-steroidal anti-inflammatory drugs (NSAID) to market.
The group specialises in reforming drugs so they are more effective and easier to take.
Shares have enjoyed around a 20% bounce since the firm recently announced it had kicked off dosing patients in a pilot study of a variation of ibuprofen.
Meanwhile, other milestones ahead include first in-human proof of concept tests for colon delivery of statins, planned in the second quarter.
House broker N+1 Singer has described the firm's prospects as "enticing" and said it had confidence in its ability in the re-formulation space.
Telling us more about the exciting catalysts ahead will be chief executive Marcelo Bravo.
Action Hotels (AIM:AHCG) is a rarity - a profitable, asset-backed, dividend paying stock.
New to the market, it is has a Kuwaiti royal, Sheikh Mubarak Al Abdullah Al-Mubarak Al-Sabah, in the driving seat.
He is chairman and a 70% shareholder.
He realised the hotel market in the Middle East, normally associated with some of the most opulent venues, was an area ripe for a midmarket (three and four-star) offering.
The group has six hotels in total - in Kuwait, Oman, Jordan and Melbourne - mainly under the Ibis fascia, although the group recently opened its first Holiday Inn and there are plans to badge some of the pipeline Premier Inns.
It listed in London on December 23, raising US$50mln, which is cash that will fully fund a further eight hotels, or 1,500 rooms, over the next three years.
Please join us at 5:45pm to allow for a prompt 6pm start. Each company has approximately 30 minutes to give a short presentation and for Q&A. This will be followed by the 'Champagne Raffle' where six guests will win a bottle each.
The evening will end with a complimentary bar and an assortment of hot and cold canapes, giving you the opportunity to speak with the directors and other investors.